Core Insights - Indivior has moved up 11 positions to the 46th spot on Barchart's Top 100 Stocks to Buy, indicating strong market interest and momentum [1] - The company has shown significant growth, with a nearly 13% increase in stock price over the past month and a remarkable 139% increase over the past 12 months [1] Financial Performance - In the first half of 2025, Indivior reported a net profit of $65 million, a 281% increase compared to a loss of $36 million in the same period the previous year [4] - On a non-GAAP basis, earnings were $121 million, down from $138 million, primarily due to previous litigation expenses [4][5] - For the full year 2025, Indivior expects top-line revenue of $1.055 billion, an increase from the previous estimate of $990 million, although down from $1.18 billion in 2024 [6] - The company anticipates adjusted EBITDA of $288 million for 2025, up from a prior estimate of $240 million [7] Product and Market Dynamics - Indivior's revenue is heavily reliant on its Sublocade product, which accounts for 70% of annual revenue, with the U.S. market contributing 93% of Sublocade revenue [8] - Despite increased competition leading to a decline in market share for its Suboxone products, Sublocade revenue is expected to rise by 3% in 2025, reaching $775 million [6]